Herantis Pharma

HRTIS

The current Herantis Pharma (HRTIS) market capitalization is approximately €52.74M, based on its latest share price and shares outstanding. Market capitalization represents the total market value of a company's equity and is calculated by multiplying the current stock price by the number of shares outstanding. As a result, Herantis Pharma's market cap fluctuates with changes in its share price and share count. Last updated: March 7, 2026 at 8:19 PM Eastern Time

In the most recently reported fiscal year, Herantis Pharma (HRTIS) generated net income of €280.00K, compared with €-9.32M in the prior fiscal year, representing a -103.00% year over year change. Net income may be positive or negative and can fluctuate materially from year to year due to changes in operating performance, non-recurring or one-time items, accounting treatments, capital structure, and broader macroeconomic conditions.

Herantis Pharma (HRTIS) does not currently pay a dividend. Over the last twelve months (LTM), the company paid €0.00 per share in dividends, and no dividend payments are currently expected over the next twelve months (NTM). Companies that do not pay dividends typically prioritize reinvesting cash into growth initiatives, capital expenditures, debt reduction, or strategic investments, though dividend policy may change in the future.

Analyst assessments of whether Herantis Pharma (HRTIS) consensus price target is overvalued or undervalued are generally expressed relative to consensus valuation frameworks and price targets, rather than as an absolute judgment.Current share price: €1.64Consensus price target: €1.55Implied return: -22.11% An implied return above current levels indicates that, on average, analysts view the stock as trading below their estimated fair value. Conversely, an implied return below current levels suggests the stock may be fully valued or priced above consensus expectations. This content is for informational purposes only and does not constitute investment advice. Last updated: April 2, 2026 at 8:14 AM Eastern Time

Based on the latest available analyst coverage, Herantis Pharma (HRTIS) currently carries a Hold consensus rating. Analysts' average HRTIS price target is €1.55. Relative to the current share price of €1.64, this suggests a potential price change of approximately -22.11%. Analyst views are forward-looking estimates and should not be considered investment advice. Last updated: April 2, 2026 at 8:14 AM Eastern Time

Like other publicly traded stocks, Herantis Pharma (HRTIS) shares are bought and sold on stock exchanges such as HLSE and other supported markets, depending on the listing. The most common way to buy shares is through an online brokerage account. To get started, you typically need to: Open an account with a licensed stock brokerComplete the broker's verification processFund your accountPlace a buy order for Herantis Pharma (HRTIS) shares Trading involves risk, and investors should consider their financial objectives and risk tolerance before investing.

At the top right of this page, you'll see a star icon labeled Add to watchlist. Click it to add HRTIS to your watchlist.

Herantis Pharma trades under the ticker symbol HRTIS on the HLSE stock exchange. The ticker HRTIS is used to identify the company's common stock across trading platforms, market data providers, and regulatory filings.

As of the most recently reported period, Herantis Pharma (HRTIS) employs approximately 13 people worldwide. Reported employee figures may fluctuate over time due to hiring activity, restructuring, automation initiatives, or changes in business strategy. Headcount data is typically disclosed in company filings and reflects full-time employees unless otherwise stated. Last updated: March 7, 2026 at 8:19 PM Eastern Time

Herantis Pharma (HRTIS) operates in a highly competitive market with companies that often have different business models, geographic exposure, and end markets. While no two companies are identical, the following firms are generally considered the closest Herantis Pharma (HRTIS) stock peers based on overlapping products, services, and competitive dynamics:H. Lundbeck (HLUN B)Financière de Tubize (TUB)Gabather (GABA)IRLAB Therapeutics (IRLAB A)AlzeCure Pharma (ALZCUR)GH Research (GHRS)Addex Therapeutics (ADXN)Jazz Pharmaceuticals (JAZZ)Newbury Pharmaceuticals (NEWBRY)Celon Pharma (CLN) These peers may differ in size, business mix, financial profile, and strategic focus, but they are commonly referenced due to overlapping markets, customer segments, or competitive positioning relative to Herantis Pharma.